Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CPT2 | P23786 | 1/20 | 0.40 |
| ▸ | CPT1A | P50416 | 1/20 | 0.40 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5018019 | 0.89 | ABL1 (0.45) | RXFP1CYP19A1NQO2LMNAKMT2A | |
| SCHEMBL5022288 | 0.82 | KDM4E (0.49) | ALDH1A1HPGDMAPK1RXFP1LMNA | |
| SCHEMBL4030576 | 0.81 | ALDH1A1 (0.47) | ALDH1A1TDP1LMNAKMT2AMAPT | |
| SCHEMBL5018020 | 0.81 | ABCB11 (0.41) | ALDH1A1HPGDMAPK1TDP1RXFP1 | |
| SCHEMBL5541552 | 0.80 | CYP1A2 (0.45) | ALDH1A1HPGDMAPK1TDP1MRGPRX4 | |
| SCHEMBL5016450 | 0.80 | PDE4D (0.57) | — | |
| SCHEMBL5016430 | 0.78 | GAA (0.43) | ALDH1A1HPGDMAPK1TDP1KMT2A | |
| SCHEMBL5016432 | 0.72 | CDK2 (0.41) | ALDH1A1RXFP1LMNAKMT2AMAPT | |
| SCHEMBL48961 | 0.71 | MRGPRX4 (0.64) | ALDH1A1HPGDMAPK1TDP1MRGPRX4 | |
| SCHEMBL30100412 | 0.71 | MRGPRX4 (0.64) | ALDH1A1HPGDMAPK1TDP1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-06-19 | — | — | US | disclosed |
| EP-1554262-B1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD (IN) | 2007-12-05 | — | — | EP | disclosed |
| US-7238725-B2 | Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2007-07-03 | — | — | US | disclosed |
| US-20060178418-A1 | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2006-08-10 | — | — | US | disclosed |
| EP-1554262-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Glenmark Pharmaceuticals Limited (IN) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004037805-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LTC4S, TSLP, GPR119 | ALDH1A1 2372/4885HPGD 807/4885MAPK1 2194/4885 |
| US-20060178418-A1 | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them | LTC4S, TSLP, GPR119 | ALDH1A1 2372/4885HPGD 807/4885MAPK1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.